MedTrace Logo

Detection of Clinically Significant Prostate Cancer Using a Urinary Multimarker Sensor

NCT04825002 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 800

Last updated 2021-04-01

No results posted yet for this study

Summary

This trial aims to develop and validate the urinary multimarker sensor which can measure trace amounts of biomarkers from naturally voided urine in men referred with clinical suspicion of prostate cancer who have had no prior prostate biopsy. The investigators hypothesize that urinary multimarker sensor will help to avoid unnecessary prostate biopsy while detect the clinically significant cancers.

Conditions

Interventions

DIAGNOSTIC_TEST

Urinary multimarker sensor

We will develop a urinary multimarker sensor, able to measure trace amounts of biomarkers from naturally voided urine.

Sponsors & Collaborators

  • Biomaterials Research Center, Korea Institute of Science and Technology (KIST), Seoul, Republic of Korea

    collaborator UNKNOWN

  • Korea Medial Device Development Fund grant funded by the Korean government

    collaborator UNKNOWN

  • Asan Medical Center

    lead OTHER

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Max Age
80 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-22
Primary Completion
2023-12-31
Completion
2023-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04825002 on ClinicalTrials.gov